[EN] SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS<br/>[FR] BENZAZINONES SUBSTITUÉS À UTILISER EN TANT QUE COMPOSÉS ANTIBACTÉRIENS
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2017098440A1
公开(公告)日:2017-06-15
The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.
Production Method of Optically Active Cyclohexane Ether Compounds
申请人:Machiya Koji
公开号:US20090005576A1
公开(公告)日:2009-01-01
The present invention relates to an industrial synthetic method of an optically active cyclohexane ether compound (IIIa) or a salt thereof, which is useful as a pharmaceutical agent, and an intermediate useful for the production method of the present invention. The production method of the present invention is as shown below: wherein each symbol is as defined in the specification. According to the production method of the present invention, efficient and stable supply of an optically active cyclohexane ether compound (IIIa) in a high yield at a lower cost can be afforded. Therefore, an optically active cyclohexane ether compound (IIIa) extremely useful as a pharmaceutical agent can be provided by an industrially highly advantageous method.
Sphingosine-1-phosphate receptor agonist and antagonist compounds
申请人:Wallace Grier A.
公开号:US20090029947A1
公开(公告)日:2009-01-29
The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
Substituted benzazinones as antibacterial compounds
申请人:GlaxoSmithKline Intellectual Property Development Limited
公开号:US10781184B2
公开(公告)日:2020-09-22
The present invention relates to LpxC antibacterial compounds of Formula (IA):
corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.